遺伝子導入技術市場 – 2029年までの世界予測

Report Overview

The global gene transfer technologies market is projected to surpass USD 5.93 billion in 2029 from USD 3.73 billion in 2024, with a significant CAGR of 9.7%. Increasing demand for personalized medicines, along with advancements in cell and gene therapies, continues to grow and contribute to a rise in this market. In addition, the increased application of gene transfer technologies in vaccine development and cancer immunotherapy boosts the segmental growth.

世界の遺伝子導入技術市場は、2024年の37億3,000万米ドルから2029年には59億3,000万米ドルを超え、9.7%という大幅なCAGRで成長すると予測されています。細胞治療や遺伝子治療の進歩に伴い、個別化医療への需要が高まり続けており、この市場の拡大に貢献しています。さらに、ワクチン開発やがん免疫療法における遺伝子導入技術の応用の増加により、セグメントの成長が促進されます。

“The viral vector gene transfer technologies segment accounted for the largest share in 2023.”

On the basis of mode, the gene transfer technologies market is further segmented into viral vector and non-viral vector. The viral vector segment is retrovirus, adenovirus, adeno associated virus (AAV) and other virus vector. The viral vector segment dominated the market in 2023, owing to superior safety and efficacy profile, minimal immunogenicity and advancements in AAV engineering.

“By application, the therapeutic application segment accounted for the largest share in the gene transfer technologies market.”

The application segment in the gene transfer technologies market is segmented into research application, therapeutic application and applications. The research application is segmented into drug discovery & development and other research application. Similarly the therapeutic application further divided into gene therapy, cell therapy, vaccines and other therapeutic application. The therapeutic application dominated the segment owing to advancements in gene transfer technologies, such as improved adeno-associated virus (AAV) & lentiviral vector and expanding application of gene therapy in cardiovascular, neurological and metabolic diseases.

“North America: the largest share of the gene transfer technologies market”

By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the gene transfer technologies market in 2023 and likely continue dominance during the forecast period. Presence of dominant market players in gene transfer technologies companies in the region, strong base of gene transfer technologies manufacturers such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany) are some of the prominent factors acerating market growth.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the gene transfer technologies market.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc. (US), Genscript (US), Bio-Techne (US), Lonza (Switzerland), Takara Bio, Inc. (Japan), Promega Corporation (US), Oxford Biomedica plc (UK) and MaxCyte (US) ) are some of the major players operating in the gene transfer technologies market.

Research Coverage:

This research report categorizes the gene transfer technologiess market product (instruments, consumables, reagents,kits & assays and other products), mode (viral vector and non viral vector), method (ex vivo, in vivo and in vitro), application (research, therapeutic and orther application) end user (pharmaceutical & biotechnology companies, academic & research institutes and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the gene transfer technologiess market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the gene transfer technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene transfer technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing demand for personalized medicines and cell & gene therapies, Increased investments in gene therapy research, Expanding applications in vaccine development & cancer immunotherapy), restraints (High costs of gene transfer systems), opportunities (Advancements in gene editing technologies and nanotechnology, Integration with digital technologies such as Al and ML) and Challenges (Scalability of production).
• Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for gene transfer technologies.
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene transfer technologies market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany) and among others in the market.

Table of Contents

1               INTRODUCTION              48

1.1           STUDY OBJECTIVES       48

1.2           MARKET DEFINITION   48

1.3           STUDY SCOPE   49

1.3.1        MARKETS COVERED AND REGIONAL SCOPE      49

1.3.2        INCLUSIONS & EXCLUSIONS       50

1.3.3        YEARS CONSIDERED      50

1.3.4        CURRENCY CONSIDERED            51

1.4           STAKEHOLDERS               51

2               RESEARCH METHODOLOGY       52

2.1           RESEARCH DATA              52

2.1.1        SECONDARY DATA          52

2.1.2        PRIMARY DATA 53

2.2           MARKET ESTIMATION METHODOLOGY               55

2.2.1        MARKET ESTIMATION  55

2.2.2        INSIGHTS FROM PRIMARY EXPERTS        57

2.2.3        TOP-DOWN APPROACH                58

2.3           MARKET GROWTH RATE PROJECTION  59

2.4           DATA TRIANGULATION                61

2.5           RESEARCH ASSUMPTIONS           61

2.6           RESEARCH LIMITATIONS             62

2.7           RISK ANALYSIS  63

3               EXECUTIVE SUMMARY  64

4               PREMIUM INSIGHTS       69

4.1           GENE DELIVERY TECHNOLOGIES MARKET OVERVIEW                 69

4.2           NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET,  BY APPLICATION (2023)          70

4.3           GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY MODE,  2024 VS. 2029     70

4.4           GENE DELIVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES            71

5               MARKET OVERVIEW       72

5.1           INTRODUCTION              72

5.2           MARKET DYNAMICS       72

5.2.1        DRIVERS               73

5.2.1.1    Growing demand for personalized medicine and cell & gene therapies                 73

5.2.1.2    Increased investments in gene therapy research              74

5.2.1.3    Expanding applications in vaccine development & cancer immunotherapy    75

5.2.2        RESTRAINTS      75

5.2.2.1    High costs of gene delivery systems  75

5.2.3        OPPORTUNITIES              76

5.2.3.1    Advancements in gene editing technologies & nanotechnology                 76

5.2.3.2    Integration with digital technologies such as AI & ML  76

5.2.4        CHALLENGES    77

5.2.4.1    Scalability of production      77

5.3           ECOSYSTEM ANALYSIS  78

5.3.1        PRODUCT PROVIDERS  78

5.3.2        END USERS         79

5.3.3        REGULATORY BODIES  79

5.4           TECHNOLOGY ANALYSIS             80

5.4.1        KEY TECHNOLOGIES     80

5.4.1.1    Microinjection       80

5.4.1.2    Electroporation     80

5.4.1.3    Sonoporation         81

5.4.2        COMPLEMENTARY TECHNOLOGIES       81

5.4.2.1    Gene editing technologies  81

5.4.2.2    Bioinformatics and computational tools           81

5.4.3        ADJCENT TECHNOLOGIES          82

5.4.3.1    Nanotechnology and nano-carriers    82

5.5           PRICING ANALYSIS          82

5.5.1        AVERAGE SELLING PRICE TREND OF REAGENTS/CONSUMABLES, BY KEY PLAYER       82

5.5.2        AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION                84

5.6           VALUE CHAIN ANALYSIS               84

5.7           SUPPLY CHAIN ANALYSIS             86

5.8           PATENT ANALYSIS          87

5.9           TRADE ANALYSIS             89

5.9.1        IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)   89

5.9.2        EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)   90

5.10         KEY CONFERENCES AND EVENTS, 2024–2025        90

5.11         REGULATORY LANDSCAPE         91

5.11.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             91

5.11.2      REGULATORY FRAMEWORK       93

5.11.2.1  North America      93

5.11.2.2  Europe   94

5.11.2.3  Asia Pacific            94

5.11.2.4  Rest of the World 95

5.12         PORTER’S FIVE FORCES ANALYSIS           96

5.12.1      THREAT OF NEW ENTRANTS      97

5.12.2      THREAT OF SUBSTITUTES          97

5.12.3      BARGAINING POWER OF BUYERS             97

5.12.4      BARGAINING POWER OF SUPPLIERS       97

5.12.5      INTENSITY OF COMPETITIVE RIVALRY 97

5.13         KEY STAKEHOLDERS AND BUYING CRITERIA     97

5.13.1      KEY STAKEHOLDERS     98

5.13.2      BUYING CRITERIA           99

5.14         INVESTMENT AND FUNDING SCENARIO               100

5.15         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       101

5.16         IMPACT OF AI/GEN AI ON GENE DELIVERY TECHNOLOGIES MARKET            102

6               GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT           104

6.1           INTRODUCTION              105

6.2           REAGENTS, KITS, AND ASSAYS  105

6.2.1        INCREASING DEMAND FOR TRANSFECTION AND GENE EDITING TOOLS TO DRIVE MARKET GROWTH  105

6.3           CONSUMABLES 109

6.3.1        RISING R&D ACTIVITY TO SUPPORT DEMAND GROWTH                 109

6.4           INSTRUMENTS 112

6.4.1        INCREASING ADOPTION OF ELECTROPORATION DEVICES TO DRIVE MARKET      112

6.5           OTHER PRODUCTS         116

7               GENE DELIVERY TECHNOLOGIES MARKET, BY MODE                 119

7.1           INTRODUCTION              120

7.2           VIRAL VECTORS                120

7.2.1        RETROVIRUSES 124

7.2.1.1    Lentiviruses           127

7.2.1.1.1 Rising disease incidence to drive market          127

7.2.1.2    Other retroviruses                 130

7.2.2        ADENOVIRUSES                133

7.2.2.1    Expansion of vaccination programs to propel market growth                 133

7.2.3        ADENO-ASSOCIATED VIRUSES  137

7.2.3.1    Low immunogenicity of AAV vectors to support adoption                 137

7.2.4        OTHER VIRAL VECTORS                140

7.3           NON-VIRAL VECTORS    143

7.3.1        CHEMICAL METHODS   147

7.3.2        LIPOSOME-MEDIATED 151

7.3.2.1    High efficiency and compatibility to drive market          151

7.3.3        CALCIUM PHOSPHATE 154

7.3.3.1    Increasing R&D in cell-based therapies to propel market growth                 154

7.3.4        DEAE-DEXTRAN               158

7.3.4.1    Simplicity and cost-effectiveness to support adoption   158

7.3.5        CATIONIC POLYMERS   161

7.3.5.1    Advancements in cationic polymer technology to drive market                 161

7.3.6        OTHER CHEMICAL METHODS   165

7.4           PHYSICAL METHODS     168

7.4.1        ELECTROPORATION      172

7.4.1.1    Rising demand for effective cell transfection technologies to drive market    172

7.4.2        MICROINJECTION           175

7.4.2.1    High accuracy and control and potential for tailored delivery to drive market          175

7.4.3        GENE GUNS        179

7.4.3.1    High efficiency of gene guns in transfecting various cell types to drive market          179

7.4.4        OTHER PHYSICAL METHODS     182

8               GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD             186

8.1           INTRODUCTION              187

8.2           IN VIVO                187

8.2.1        EMERGENCE OF MRNA-BASED VACCINES TO PROPEL IN VIVO GENE DELIVERY APPLICATIONS              187

8.3           EX VIVO                191

8.3.1        SUCCESSFUL COMMERCIALIZATION OF CAR T-CELL THERAPIES TO DRIVE THE EX VIVO GENE DELIVERY MARKET                 191

8.4           IN VITRO              194

8.4.1        DATABASES MAJORLY CONTRIBUTE TO STORING GENE DELIVERY TECHNOLOGIES AND INTEGRATING OTHER OMICS DATABASES.      194

9               GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION   198

9.1           INTRODUCTION              199

9.2           THERAPEUTIC APPLICATIONS  199

9.2.1        GENE THERAPY                 203

9.2.1.1    Increasing demand for personalized medicine to support market growth    203

9.2.2        CELL THERAPY 206

9.2.2.1    Rising government funding to propel market growth     206

9.2.3        VACCINES           209

9.2.3.1    Rising prevalence of infectious diseases to drive market growth                 209

9.2.4        OTHER THERAPEUTIC APPLICATIONS  213

9.3           RESEARCH APPLICATIONS          216

9.3.1        DRUG DISCOVERY & DEVELOPMENT     220

9.3.1.1    Increased funding for gene therapy research to drive market growth    220

9.3.1.2    Cancer    224

9.3.1.2.1 Rising investment in cancer research to drive market    224

9.3.2        INFECTIOUS DISEASES 228

9.3.2.1    Rising incidence of infectious disease to drive market growth                 228

9.3.3        GENETIC & NEUROLOGICAL DISORDERS             231

9.3.3.1    Rising burden of disorders to drive market      231

9.3.4        AUTOIMMUNE DISEASES             235

9.3.4.1    Growing prevalence of autoimmune disorders to ensure demand for therapeutic solutions     235

9.3.5        OTHER DISEASES             238

9.3.6        OTHER RESEARCH APPLICATIONS          242

9.4           OTHER APPLICATIONS 245

10            GENE DELIVERY TECHNOLOGIES MARKET, BY END USER     249

10.1         INTRODUCTION              250

10.2         PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 250

10.2.1      PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET         250

10.3         ACADEMIC & RESEARCH INSTITUTES    254

10.3.1      INCREASING R&D AND GROWING FUNDING AND PARTNERSHIPS TO PROMOTE MARKET GROWTH            254

10.4         OTHER END USERS         257

11            GENE DELIVERY TECHNOLOGIES MARKET, BY REGION                 261

11.1         INTRODUCTION              262

11.2         NORTH AMERICA             262

11.2.1      NORTH AMERICA: MACROECONOMIC OUTLOOK                 263

11.2.2      US           269

11.2.2.1  US to dominate North American market over forecast period                 269

11.2.3      CANADA               274

11.2.3.1  Strong infrastructure and availability of funding for biomedical research to support market growth    274

11.3         EUROPE               279

11.3.1      EUROPE: MACROECONOMIC OUTLOOK               280

11.3.2      GERMANY           285

11.3.2.1  Germany to hold largest market share in Europe            285

11.3.3      UK          291

11.3.3.1  Increasing government funding to drive market growth                 291

11.3.4      FRANCE                296

11.3.4.1  Rising support for genetic research to offer potential growth opportunities         296

11.3.5      ITALY    301

11.3.5.1  Rising R&D and support for gene delivery to drive market                 301

11.3.6      SPAIN    306

11.3.6.1  Growing expansion of research centers to stimulate market                 306

11.3.7      REST OF EUROPE             311

11.4         ASIA PACIFIC     316

11.4.1      ASIA PACIFIC: MACROECONOMIC OUTLOOK     316

11.4.2      CHINA  323

11.4.2.1  Increasing R&D expenditure to drive market growth     323

11.4.3      JAPAN   328

11.4.3.1  Rising research into precision medicine to support market growth                 328

11.4.4      INDIA    334

11.4.4.1  Strong research base and rising FDI in pharma sector to support market growth       334

11.4.5      SOUTH KOREA  339

11.4.5.1  Alliances & investments in research to drive market      339

11.4.6      AUSTRALIA         344

11.4.6.1  Increasing focus on precision medicine to offer significant growth opportunities         344

11.4.7      REST OF ASIA PACIFIC   349

11.5         LATIN AMERICA                354

11.5.1      LATIN AMERICA: MACROECONOMIC OUTLOOK                 354

11.5.2      BRAZIL 360

11.5.2.1  Brazil to hold largest market share in LATAM                360

11.5.3      MEXICO                365

11.5.3.1  Strong pharmaceutical industry and increased government support to augment market growth   365

11.5.4      REST OF LATIN AMERICA             370

11.6         MIDDLE EAST   375

11.6.1      MIDDLE EAST: MACROECONOMIC OUTLOOK   375

11.6.2      GCC COUNTRIES              381

11.6.2.1  Saudi Arabia          386

11.6.2.1.1                Increasing government investments in healthcare and growing pharmaceuticals industry to support market     386

11.6.2.2  UAE        392

11.6.2.2.1                Growing R&D expenditure and infrastructural development to drive market              392

11.6.2.3  Rest of GCC Countries        397

11.6.3      REST OF MIDDLE EAST 403

11.7         AFRICA 408

11.7.1      RISING EMPHASIS ON GENE DELIVERY TECHNOLOGIES FOR THERAPEUTICS TO SUPPORT MARKET GROWTH   408

11.7.2      MACROECONOMIC OUTLOOK FOR AFRICA        409

12            COMPETITIVE LANDSCAPE         415

12.1         OVERVIEW          415

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            415

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET          415

12.3         REVENUE ANALYSIS       417

12.4         MARKET SHARE ANALYSIS           417

12.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 419

12.5.1      STARS   419

12.5.2      EMERGING LEADERS     419

12.5.3      PERVASIVE PLAYERS      420

12.5.4      PARTICIPANTS 420

12.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         421

12.5.5.1  Company footprint               421

12.5.5.2  Region footprint   421

12.5.5.3  Product footprint  422

12.5.5.4  Method footprint  423

12.5.5.5  Application footprint            424

12.5.5.6  End-user footprint                425

12.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        425

12.6.1      PROGRESSIVE COMPANIES         425

12.6.2      RESPONSIVE COMPANIES            425

12.6.3      DYNAMIC COMPANIES  426

12.6.4      STARTING BLOCKS         426

12.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 427

12.7         COMPANY VALUATION & FINANCIAL METRICS 428

12.7.1      FINANCIAL METRICS      428

12.7.2      COMPANY VALUATION 428

12.8         BRAND/PRODUCT COMPARISON             429

12.9         COMPETITIVE SCENARIO             430

12.9.1      PRODUCT LAUNCHES   430

12.9.2      DEALS  431

12.9.3      EXPANSIONS     432

13            COMPANY PROFILES      433

13.1         KEY PLAYERS     433

13.1.1      THERMO FISHER SCIENTIFIC INC.            433

13.1.1.1  Business overview 433

13.1.1.2  Products/Services/Solutions offered 434

13.1.1.3  Recent developments           441

13.1.1.3.1                Product launches  441

13.1.1.3.2                Expansions             441

13.1.1.4  MnM view              441

13.1.1.4.1                Key strengths        441

13.1.1.4.2                Strategic choices   442

13.1.1.4.3                Weaknesses and competitive threats 442

13.1.2      DANAHER CORPORATION           443

13.1.2.1  Business overview 443

13.1.2.2  Products/Services/Solutions offered 444

13.1.2.3  Recent developments           446

13.1.2.3.1                Product launches  446

13.1.2.3.2                Deals      447

13.1.2.3.3                Expansions             447

13.1.2.4  MnM view              447

13.1.2.4.1                Key strengths        447

13.1.2.4.2                Strategic choices   448

13.1.2.4.3                Weaknesses and competitive threats 448

13.1.3      MERCK KGAA    449

13.1.3.1  Business overview 449

13.1.3.2  Products/Services/Solutions offered 450

13.1.3.3  Recent developments           453

13.1.3.3.1                Deals      453

13.1.3.3.2                Expansions             454

13.1.3.4  MnM view              454

13.1.3.4.1                Key strengths        454

13.1.3.4.2                Strategic choices   454

13.1.3.4.3                Weaknesses and competitive threats 454

13.1.4      BIO-RAD LABORATORIES, INC.  455

13.1.4.1  Business overview 455

13.1.4.2  Products/Services/Solutions offered 456

13.1.5      AGILENT TECHNOLOGIES, INC.                458

13.1.5.1  Business overview 458

13.1.5.2  Products/Services/Solutions offered 459

13.1.5.3  Recent developments           461

13.1.5.3.1                Deals      461

13.1.6      REVVITY               462

13.1.6.1  Business overview 462

13.1.6.2  Products/Services/Solutions offered 463

13.1.6.3  Recent developments           465

13.1.6.3.1                Product launches  465

13.1.6.3.2                Deals      465

13.1.7      QIAGEN                466

13.1.7.1  Business overview 466

13.1.7.2  Products/Services/Solutions offered 467

13.1.8      GENSCRIPT        469

13.1.8.1  Business overview 469

13.1.8.2  Products/Services/Solutions offered 470

13.1.8.3  Recent developments           471

13.1.8.3.1                Deals      471

13.1.9      TAKARA BIO INC.             472

13.1.9.1  Business overview 472

13.1.9.2  Products/Services/Solutions offered 473

13.1.9.3  Recent developments           479

13.1.9.3.1                Product launches  479

13.1.9.3.2                Deals      479

13.1.10   PROMEGA CORPORATION           480

13.1.10.1                 Business overview 480

13.1.10.2                 Products/Services/Solutions offered 480

13.1.11   BIO-TECHNE     482

13.1.11.1                 Business overview 482

13.1.11.2                 Products/Services/Solutions offered 483

13.1.11.3                 Recent developments           485

13.1.11.3.1             Product launches  485

13.1.12   LONZA 486

13.1.12.1                 Business overview 486

13.1.12.2                 Products/Services/Solutions offered 487

13.1.12.3                 Recent developments           489

13.1.12.3.1             Product launches  489

13.1.12.3.2             Deals      489

13.1.13   OXFORD BIOMEDICA PLC            490

13.1.13.1                 Business overview 490

13.1.13.2                 Products/Services/Solutions offered 491

13.1.13.3                 Recent developments           492

13.1.13.3.1             Product launches  492

13.1.13.3.2             Deals      492

13.1.13.3.3             Other developments             493

13.1.14   SARTORIUS AG 494

13.1.14.1                 Business overview 494

13.1.14.2                 Products/Services/Solutions offered 495

13.1.14.3                 Recent developments           497

13.1.14.3.1             Product launches  497

13.1.14.3.2             Deals      497

13.1.15   MAXCYTE            498

13.1.15.1                 Business overview 498

13.1.15.2                 Products/Services/Solutions offered 499

13.1.15.3                 Recent developments           500

13.1.15.3.1             Deals      500

13.2         OTHER PLAYERS              503

13.2.1      CELL BIOLABS, INC.        503

13.2.2      GENTARGET INC.             505

13.2.3      ORIGENE TECHNOLOGIES, INC.                507

13.2.4      ALTOGEN BIOSYSTEMS 508

13.2.5      OZ BIOSCIENCES             510

13.2.6      GENECOPOEIA, INC.       512

13.2.7      CREATIVE BIOLABS        513

13.2.8      SYNBIO TECHNOLOGIES LLC     513

13.2.9      SYSTEM BIOSCIENCES, LLC         514

13.2.10   VECTORBUILDER INC.  515

14            APPENDIX           517

14.1         DISCUSSION GUIDE        517

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL                521

14.3         CUSTOMIZATION OPTIONS        523

14.4         RELATED REPORTS         523

14.5         AUTHOR DETAILS           524

LIST OF TABLES

TABLE 1                IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS              60

TABLE 2                GENE DELIVERY TECHNOLOGIES MARKET: RISK ASSESSMENT ANALYSIS      63

TABLE 3                GENE DELIVERY TECHNOLOGY MARKET: KEY PRODUCT PROVIDERS  78

TABLE 4                GENE DELIVERY TECHNOLOGY MARKET: KEY END USERS         79

TABLE 5                GENE DELIVERY TECHNOLOGY MARKET: REGULATORY BODIES  80

TABLE 6                AVERAGE SELLING PRICE TREND OF GENE DELIVERY REAGENTS/CONSUMABLES,  BY KEY PLAYERS, 2021–2023        83

TABLE 7                KEY PATENTS IN GENE DELIVERY TECHNOLOGIES MARKET, 2021–2024       88

TABLE 8                IMPORT VOLUME FOR HS CODE 854330, 2019–2023 (UNITS)      89

TABLE 9                EXPORT VOLUME FOR HS CODE 854330, 2019–2023 (UNITS)      90

TABLE 10              GENE DELIVERY TECHNOLOGIES MARKET: DETAILED LIST OF CONFERENCES & EVENTS    90

TABLE 11              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 91

TABLE 12              EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 92

TABLE 13              ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 92

TABLE 14              REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             93

TABLE 15              GENE DELIVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS           96

TABLE 16              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS  98

TABLE 17              GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            105

TABLE 18              GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY REGION,

2022–2029 (USD MILLION)            106

TABLE 19              NORTH AMERICA: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               106

TABLE 20              EUROPE: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            107

TABLE 21             ASIA PACIFIC: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               107

TABLE 22              LATIN AMERICA: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               108

TABLE 23              MIDDLE EAST: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,

BY REGION, 2022–2029 (USD MILLION)   108

TABLE 24              GCC COUNTRIES: GENE DELIVERY REAGENTS, KITS, AND ASSAYS MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               108

TABLE 25              GENE DELIVERY CONSUMABLES MARKET, BY REGION, 2022–2029 (USD MILLION)          109

TABLE 26              NORTH AMERICA: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            110

TABLE 27              EUROPE: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          110

TABLE 28              ASIA PACIFIC: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            111

TABLE 29              LATIN AMERICA: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            111

TABLE 30              MIDDLE EAST: GENE DELIVERY CONSUMABLES MARKET, BY REGION,

2022–2029 (USD MILLION)            111

TABLE 31              GCC COUNTRIES: GENE DELIVERY CONSUMABLES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            112

TABLE 32              GENE DELIVERY INSTRUMENTS MARKET, BY REGION, 2022–2029 (USD MILLION)          113

TABLE 33              NORTH AMERICA: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            113

TABLE 34              EUROPE: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            114

TABLE 35              ASIA PACIFIC: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            114

TABLE 36              LATIN AMERICA: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          115

TABLE 37              MIDDLE EAST: GENE DELIVERY INSTRUMENTS MARKET, BY REGION,

2022–2029 (USD MILLION)            115

TABLE 38              GCC COUNTRIES: GENE DELIVERY INSTRUMENTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            115

TABLE 39              OTHER GENE DELIVERY PRODUCTS MARKET, BY REGION,

2022–2029 (USD MILLION)            116

TABLE 40              OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            116

TABLE 41              EUROPE: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            117

TABLE 42              ASIA PACIFIC: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            117

TABLE 43              LATIN AMERICA: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)                 118

TABLE 44              MIDDLE EAST: OTHER GENE DELIVERY PRODUCTS MARKET, BY REGION,

2022–2029 (USD MILLION)            118

TABLE 45              GCC COUNTRIES: OTHER GENE DELIVERY PRODUCTS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)                 118

TABLE 46              GENE DELIVERY TECHNOLOGIES MARKET BY MODE, 2022–2029 (USD MILLION)             120

TABLE 47              VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            121

TABLE 48              VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            121

TABLE 49              NORTH AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 121

TABLE 50              EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               122

TABLE 51              ASIA PACIFIC: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               122

TABLE 52              LATIN AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 123

TABLE 53              MIDDLE EAST: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION) 123

TABLE 54              GCC COUNTRIES: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 123

TABLE 55              RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            124

TABLE 56              RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            125

TABLE 57              NORTH AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 125

TABLE 58              EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               125

TABLE 59              ASIA PACIFIC: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               126

TABLE 60              LATIN AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 126

TABLE 61              MIDDLE EAST: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   126

TABLE 62              GCC COUNTRIES: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 127

TABLE 63              LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            128

TABLE 64              NORTH AMERICA: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 128

TABLE 65              EUROPE: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               128

TABLE 66              ASIA PACIFIC: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               129

TABLE 67              LATIN AMERICA: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               129

TABLE 68              MIDDLE EAST: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   129

TABLE 69              GCC COUNTRIES: LENTIVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 130

TABLE 70              OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   130

TABLE 71              NORTH AMERICA: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       131

TABLE 72              EUROPE: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 131

TABLE 73              ASIA PACIFIC: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            132

TABLE 74              LATIN AMERICA: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       132

TABLE 75              MIDDLE EAST: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION)       132

TABLE 76              GCC COUNTRIES: OTHER RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       133

TABLE 77              ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            134

TABLE 78              NORTH AMERICA: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 134

TABLE 79              EUROPE: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               135

TABLE 80              ASIA PACIFIC: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               135

TABLE 81              LATIN AMERICA: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 136

TABLE 82              MIDDLE EAST: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   136

TABLE 83              GCC COUNTRIES: ADENOVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 136

TABLE 84              AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            137

TABLE 85              NORTH AMERICA: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               138

TABLE 86              EUROPE: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            138

TABLE 87              ASIA PACIFIC: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)            138

TABLE 88              LATIN AMERICA: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               139

TABLE 89              MIDDLE EAST: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            139

TABLE 90              GCC COUNTRIES: AAV-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY,  2022–2029 (USD MILLION)            139

TABLE 91              OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   140

TABLE 92              NORTH AMERICA: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     141

TABLE 93              EUROPE: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 141

TABLE 94              ASIA PACIFIC: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            142

TABLE 95              LATIN AMERICA: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       142

TABLE 96              MIDDLE EAST: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION)       142

TABLE 97              GCC COUNTRIES: OTHER VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     143

TABLE 98              NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)                 144

TABLE 99              NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            144

TABLE 100            NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       144

TABLE 101            EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 145

TABLE 102            ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            145

TABLE 103            LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            146

TABLE 104            MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION)       146

TABLE 105            GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       146

TABLE 106            CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            147

TABLE 107            CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            148

TABLE 108            NORTH AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               148

TABLE 109            EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            149

TABLE 110            ASIA PACIFIC: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            149

TABLE 111            LATIN AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               150

TABLE 112            MIDDLE EAST: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            150

TABLE 113            GCC COUNTRIES: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY,  2022–2029 (USD MILLION)            150

TABLE 114            LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            151

TABLE 115            NORTH AMERICA: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 152

TABLE 116            EUROPE: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               152

TABLE 117            ASIA PACIFIC: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               153

TABLE 118            LATIN AMERICA: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 153

TABLE 119            MIDDLE EAST: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION) 153

TABLE 120            GCC COUNTRIES: LIPOSOME-MEDIATED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 154

TABLE 121            CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   155

TABLE 122            NORTH AMERICA: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     155

TABLE 123            EUROPE: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 156

TABLE 124            ASIA PACIFIC: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       156

TABLE 125            LATIN AMERICA: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       157

TABLE 126            MIDDLE EAST: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)       157

TABLE 127            GCC COUNTRIES: CALCIUM PHOSPHATE-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)     157

TABLE 128            DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            158

TABLE 129            NORTH AMERICA: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            159

TABLE 130            EUROPE: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               159

TABLE 131            ASIA PACIFIC: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 160

TABLE 132            LATIN AMERICA: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 160

TABLE 133            MIDDLE EAST: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION) 160

TABLE 134            GCC COUNTRIES: DEAE-DEXTRAN-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            161

TABLE 135            CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            162

TABLE 136            NORTH AMERICA: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       162

TABLE 137            EUROPE: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 163

TABLE 138            ASIA PACIFIC: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            163

TABLE 139            LATIN AMERICA: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       164

TABLE 140            MIDDLE EAST: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION)       164

TABLE 141            GCC COUNTRIES: CATIONIC POLYMER-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       164

TABLE 142            OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            165

TABLE 143            NORTH AMERICA: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               166

TABLE 144            EUROPE: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               166

TABLE 145            ASIA PACIFIC: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)             167

TABLE 146            LATIN AMERICA: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               167

TABLE 147            MIDDLE EAST: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   167

TABLE 148            GCC COUNTRIES: OTHER CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               168

TABLE 149            PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            168

TABLE 150            PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)          169

TABLE 151            NORTH AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               169

TABLE 152            EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            170

TABLE 153            ASIA PACIFIC: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            170

TABLE 154            LATIN AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               171

TABLE 155            MIDDLE EAST: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            171

TABLE 156            GCC COUNTRIES: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY,  2022–2029 (USD MILLION)            171

TABLE 157            ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            172

TABLE 158            NORTH AMERICA: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       173

TABLE 159            EUROPE: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 173

TABLE 160            ASIA PACIFIC: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            174

TABLE 161            LATIN AMERICA: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            174

TABLE 162            MIDDLE EAST: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION)       174

TABLE 163            GCC COUNTRIES: ELECTROPORATION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)       175

TABLE 164            MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,  2022–2029 (USD MILLION)            176

TABLE 165            NORTH AMERICA: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            176

TABLE 166            EUROPE: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               177

TABLE 167            ASIA PACIFIC: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 177

TABLE 168            LATIN AMERICA: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            178

TABLE 169            MIDDLE EAST: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY REGION, 2022–2029 (USD MILLION) 178

TABLE 170            GCC COUNTRIES: MICROINJECTION-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)            178

TABLE 171            GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            179

TABLE 172            NORTH AMERICA: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION) 180

TABLE 173            EUROPE: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               180

TABLE 174            ASIA PACIFIC: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               181

TABLE 175            LATIN AMERICA: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               181

TABLE 176            MIDDLE EAST: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   181

TABLE 177            GCC COUNTRIES: GENE GUN-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               182

TABLE 178            OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            183

TABLE 179            NORTH AMERICA: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)             183

TABLE 180            EUROPE: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               184

TABLE 181            ASIA PACIFIC: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               184

TABLE 182            LATIN AMERICA: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               185

TABLE 183            MIDDLE EAST: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY REGION, 2022–2029 (USD MILLION)   185

TABLE 184            GCC COUNTRIES: OTHER PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               185

TABLE 185            GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            187

TABLE 186            IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            188

TABLE 187            NORTH AMERICA: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            188

TABLE 188            EUROPE: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            189

TABLE 189            ASIA PACIFIC: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            189

TABLE 190            LATIN AMERICA: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            190

TABLE 191            MIDDLE EAST: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            190

TABLE 192            GCC COUNTRIES: IN VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            190

TABLE 193            EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            191

TABLE 194            NORTH AMERICA: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            192

TABLE 195            EUROPE: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            192

TABLE 196            ASIA PACIFIC: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            193

TABLE 197            LATIN AMERICA: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            193

TABLE 198            MIDDLE EAST: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            193

TABLE 199            GCC COUNTRIES: EX VIVO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            194

TABLE 200            IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            195

TABLE 201            NORTH AMERICA: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY, 2022–2029 (USD MILLION)               195

TABLE 202            EUROPE: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            196

TABLE 203            ASIA PACIFIC: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            196

TABLE 204            LATIN AMERICA: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            197

TABLE 205            MIDDLE EAST: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)            197

TABLE 206            GCC COUNTRIES: IN VITRO GENE DELIVERY TECHNOLOGIES MARKET,

BY COUNTRY,  2022–2029 (USD MILLION)            197

TABLE 207            GENE DELIVERY TECHNOLOGIES MARKET BY APPLICATION,

2022–2029 (USD MILLION)            199

TABLE 208            GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,

BY TYPE, 2022–2029 (USD MILLION)         200

TABLE 209            GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,

BY REGION, 2022–2029 (USD MILLION)   200

TABLE 210            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)               200

TABLE 211            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)            201

TABLE 212            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)            201

TABLE 213            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)               202

TABLE 214            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)   202

TABLE 215            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)               202

TABLE 216            GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY, BY REGION,  2022–2029 (USD MILLION)                 203

TABLE 217            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,  BY COUNTRY, 2022–2029 (USD MILLION)            204

TABLE 218            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,

BY COUNTRY, 2022–2029 (USD MILLION)               204

TABLE 219            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,

BY COUNTRY, 2022–2029 (USD MILLION)               205

TABLE 220            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,  BY COUNTRY, 2022–2029 (USD MILLION)            205

TABLE 221            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,

BY REGION,  2022–2029 (USD MILLION)              205

TABLE 222            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR GENE THERAPY,  BY COUNTRY, 2022–2029 (USD MILLION)            206

TABLE 223            GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY, BY REGION,

2022–2029 (USD MILLION)            207

TABLE 224            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,  BY COUNTRY, 2022–2029 (USD MILLION)            207

TABLE 225            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,

BY COUNTRY, 2022–2029 (USD MILLION)               207

TABLE 226            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,

BY COUNTRY, 2022–2029 (USD MILLION)               208

TABLE 227            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,

BY COUNTRY, 2022–2029 (USD MILLION)               208

TABLE 228            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,

BY REGION,  2022–2029 (USD MILLION)                 208

TABLE 229            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR CELL THERAPY,  BY COUNTRY, 2022–2029 (USD MILLION)            209

TABLE 230            GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY REGION,

2022–2029 (USD MILLION)            210

TABLE 231            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,

BY COUNTRY, 2022–2029 (USD MILLION)               210

TABLE 232            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION)            211

TABLE 233            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,

BY COUNTRY, 2022–2029 (USD MILLION)               211

TABLE 234            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,

BY COUNTRY, 2022–2029 (USD MILLION)               212

TABLE 235            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,

BY REGION,  2022–2029 (USD MILLION)                 212

TABLE 236            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR VACCINES,

BY COUNTRY,  2022–2029 (USD MILLION)            212

TABLE 237            GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS,  BY REGION, 2022–2029 (USD MILLION) 213

TABLE 238            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                 214

TABLE 239            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     214

TABLE 240            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     215

TABLE 241            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                 215

TABLE 242            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)  215

TABLE 243            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                 216

TABLE 244            GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,

BY TYPE,  2022–2029 (USD MILLION)      217

TABLE 245            GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,

BY REGION, 2022–2029 (USD MILLION)   217

TABLE 246            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     217

TABLE 247            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)       218

TABLE 248            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)       218

TABLE 249            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     219

TABLE 250            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)          219

TABLE 251            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     219

TABLE 252            GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT,  BY TYPE, 2022–2029 (USD MILLION)            221

TABLE 253            GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT,  BY REGION, 2022–2029 (USD MILLION) 221

TABLE 254            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)                 222

TABLE 255            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)     222

TABLE 256            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)     223

TABLE 257            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)                 223

TABLE 258            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION) 223

TABLE 259            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2022–2029 (USD MILLION)                 224

TABLE 260            GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY REGION,

2022–2029 (USD MILLION)            225

TABLE 261            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,

BY COUNTRY, 2022–2029 (USD MILLION)               225

TABLE 262            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)                 226

TABLE 263            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,

BY COUNTRY, 2022–2029 (USD MILLION)               226

TABLE 264            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,

BY COUNTRY, 2022–2029 (USD MILLION)             227

TABLE 265            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,

BY REGION,  2022–2029 (USD MILLION)                 227

TABLE 266            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR CANCER,

BY COUNTRY,  2022–2029 (USD MILLION)            227

TABLE 267            GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION,  2022–2029 (USD MILLION)                 228

TABLE 268            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)     229

TABLE 269            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION) 229

TABLE 270            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION) 230

TABLE 271            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)     230

TABLE 272            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES,  BY REGION, 2022–2029 (USD MILLION)          230

TABLE 273            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)     231

TABLE 274            GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION) 232

TABLE 275            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)    232

TABLE 276            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)     233

TABLE 277            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)     233

TABLE 278            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)    234

TABLE 279            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY REGION, 2022–2029 (USD MILLION)         234

TABLE 280            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR GENETIC & NEUROLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)    234

TABLE 281            GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES,

BY REGION, 2022–2029 (USD MILLION)   235

TABLE 282            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)     236

TABLE 283            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)       236

TABLE 284            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)       237

TABLE 285            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)     237

TABLE 286            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES,  BY REGION, 2022–2029 (USD MILLION)          237

TABLE 287            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)     238

TABLE 288            GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES, BY REGION,  2022–2029 (USD MILLION)                 239

TABLE 289            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)     239

TABLE 290            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)               240

TABLE 291            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES,

BY COUNTRY, 2022–2029 (USD MILLION)             240

TABLE 292            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)     241

TABLE 293            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES,  BY REGION, 2022–2029 (USD MILLION)            241

TABLE 294            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)     241

TABLE 295            GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS,  BY REGION, 2022–2029 (USD MILLION) 242

TABLE 296            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                 243

TABLE 297            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)            243

TABLE 298            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)            244

TABLE 299            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                 244

TABLE 300            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)  244

TABLE 301            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)                 245

TABLE 302            GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION,  2022–2029 (USD MILLION)                 246

TABLE 303            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     246

TABLE 304            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD MILLION)               247

TABLE 305            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION) 247

TABLE 306            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS,  BY COUNTRY, 2022–2029 (USD MILLION)     248

TABLE 307            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS,  BY REGION, 2022–2029 (USD MILLION)          248

TABLE 308            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)     248

TABLE 309            GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            250

TABLE 310            GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)          251

TABLE 311            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,

2022–2029 (USD MILLION)            251

TABLE 312            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)   252

TABLE 313            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)   252

TABLE 314            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)            253

TABLE 315            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)            253

TABLE 316            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,

2022–2029 (USD MILLION)            253

TABLE 317            GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES,  BY REGION, 2022–2029 (USD MILLION) 254

TABLE 318            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)   255

TABLE 319            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)     255

TABLE 320            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)     256

TABLE 321            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)   256

TABLE 322            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)        256

TABLE 323            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)   257

TABLE 324            GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION,  2022–2029 (USD MILLION)                 258

TABLE 325            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS,  BY COUNTRY, 2022–2029 (USD MILLION)     258

TABLE 326            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS,

BY COUNTRY,  2022–2029 (USD MILLION)            259

TABLE 327            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS,  BY COUNTRY, 2022–2029 (USD MILLION) 259

TABLE 328            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS,  BY COUNTRY, 2022–2029 (USD MILLION)     260

TABLE 329            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS,  BY REGION, 2022–2029 (USD MILLION)            260

TABLE 330            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR OTHER END USERS,  BY COUNTRY, 2022–2029 (USD MILLION)     260

TABLE 331            GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)            262

TABLE 332            NORTH AMERICA: KEY MACROINDICATORS                 263

TABLE 333            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            264

TABLE 334            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            265

TABLE 335            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            265

TABLE 336            NORTH AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            265

TABLE 337            NORTH AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            266

TABLE 338            NORTH AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 266

TABLE 339            NORTH AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 266

TABLE 340            NORTH AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 267

TABLE 341            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            267

TABLE 342            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,  2022–2029 (USD MILLION)            267

TABLE 343            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                268

TABLE 344            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      268

TABLE 345            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         268

TABLE 346            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,  2022–2029 (USD MILLION)            269

TABLE 347            US: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            270

TABLE 348            US: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            270

TABLE 349            US: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 270

TABLE 350            US: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 271

TABLE 351            US: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         271

TABLE 352            US: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            271

TABLE 353            US: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            272

TABLE 354            US: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            272

TABLE 355            US: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            272

TABLE 356            US: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2022–2029 (USD MILLION)         273

TABLE 357            US: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 273

TABLE 358            US: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)            273

TABLE 359            US: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            274

TABLE 360            CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            275

TABLE 361            CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            275

TABLE 362            CANADA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         275

TABLE 363            CANADA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 276

TABLE 364            CANADA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         276

TABLE 365            CANADA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            276

TABLE 366            CANADA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            277

TABLE 367            CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            277

TABLE 368            CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            277

TABLE 369            CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 278

TABLE 370            CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            278

TABLE 371            CANADA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       278

TABLE 372            CANADA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            279

TABLE 373            EUROPE: KEY MACROINDICATORS          280

TABLE 374            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            281

TABLE 375            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            281

TABLE 376            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            281

TABLE 377            EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         282

TABLE 378            EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 282

TABLE 379            EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         282

TABLE 380            EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            283

TABLE 381            EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            283

TABLE 382            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            283

TABLE 383            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            284

TABLE 384            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 284

TABLE 385            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            284

TABLE 386            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       285

TABLE 387            EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            285

TABLE 388            GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            286

TABLE 389            GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            287

TABLE 390            GERMANY: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         287

TABLE 391            GERMANY: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         287

TABLE 392            GERMANY: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            288

TABLE 393            GERMANY: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            288

TABLE 394            GERMANY: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            288

TABLE 395            GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            289

TABLE 396            GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            289

TABLE 397            GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 289

TABLE 398            GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            290

TABLE 399            GERMANY: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)       290

TABLE 400            GERMANY: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            290

TABLE 401            UK: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            291

TABLE 402            UK: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            292

TABLE 403            UK: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 292

TABLE 404            UK: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 292

TABLE 405            UK: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         293

TABLE 406            UK: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            293

TABLE 407            UK: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            293

TABLE 408            UK: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            294

TABLE 409            UK: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            294

TABLE 410            UK: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2022–2029 (USD MILLION)         294

TABLE 411            UK: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 295

TABLE 412            UK: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)            295

TABLE 413            UK: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            295

TABLE 414            FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            296

TABLE 415            FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            297

TABLE 416            FRANCE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         297

TABLE 417            FRANCE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 297

TABLE 418            FRANCE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         298

TABLE 419            FRANCE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            298

TABLE 420            FRANCE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            298

TABLE 421            FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)          299

TABLE 422            FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            299

TABLE 423            FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 299

TABLE 424            FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            300

TABLE 425            FRANCE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       300

TABLE 426            FRANCE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            301

TABLE 427            ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            302

TABLE 428            ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            302

TABLE 429            ITALY: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 302

TABLE 430            ITALY: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 303

TABLE 431            ITALY: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         303

TABLE 432            ITALY: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)          303

TABLE 433            ITALY: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            304

TABLE 434            ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)          304

TABLE 435            ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            304

TABLE 436            ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 305

TABLE 437            ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            305

TABLE 438            ITALY: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       305

TABLE 439            ITALY: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)          306

TABLE 440            SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            307

TABLE 441            SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            307

TABLE 442            SPAIN: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 307

TABLE 443            SPAIN: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 308

TABLE 444            SPAIN: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         308

TABLE 445            SPAIN: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            308

TABLE 446            SPAIN: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            309

TABLE 447            SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            309

TABLE 448            SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            309

TABLE 449            SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 310

TABLE 450            SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            310

TABLE 451            SPAIN: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       310

TABLE 452            SPAIN: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)          311

TABLE 453            REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,  2022–2029 (USD MILLION)            312

TABLE 454            REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)          312

TABLE 455            REST OF EUROPE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            312

TABLE 456            REST OF EUROPE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            313

TABLE 457            REST OF EUROPE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 313

TABLE 458            REST OF EUROPE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 313

TABLE 459            REST OF EUROPE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 314

TABLE 460            REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            314

TABLE 461            REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,  2022–2029 (USD MILLION)            314

TABLE 462            REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                315

TABLE 463            REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      315

TABLE 464            REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         315

TABLE 465            REST OF EUROPE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,  2022–2029 (USD MILLION)            316

TABLE 466            ASIA PACIFIC: KEY MACROINDICATORS                 317

TABLE 467            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          319

TABLE 468            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)          319

TABLE 469            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            319

TABLE 470            ASIA PACIFIC: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)       320

TABLE 471            ASIA PACIFIC: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         320

TABLE 472            ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)       320

TABLE 473            ASIA PACIFIC: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 321

TABLE 474            ASIA PACIFIC: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 321

TABLE 475            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)          321

TABLE 476            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            322

TABLE 477            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 322

TABLE 478            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            322

TABLE 479            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)       323

TABLE 480            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            323

TABLE 481            CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)          324

TABLE 482            CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)          324

TABLE 483            CHINA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 325

TABLE 484            CHINA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 325

TABLE 485            CHINA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         325

TABLE 486            CHINA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            326

TABLE 487            CHINA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)          326

TABLE 488            CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            326

TABLE 489            CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            327

TABLE 490            CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 327

TABLE 491            CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            327

TABLE 492            CHINA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       328

TABLE 493            CHINA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)          328

TABLE 494            JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            329

TABLE 495            JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            330

TABLE 496            JAPAN: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 330

TABLE 497            JAPAN: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 330

TABLE 498            JAPAN: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         331

TABLE 499            JAPAN: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            331

TABLE 500            JAPAN: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            331

TABLE 501            JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            332

TABLE 502            JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          332

TABLE 503            JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 332

TABLE 504            JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            333

TABLE 505            JAPAN: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       333

TABLE 506            JAPAN: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            334

TABLE 507            INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            335

TABLE 508            INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            335

TABLE 509            INDIA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 335

TABLE 510            INDIA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 336

TABLE 511            INDIA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         336

TABLE 512            INDIA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            336

TABLE 513            INDIA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            337

TABLE 514            INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            337

TABLE 515            INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            337

TABLE 516            INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION) 338

TABLE 517            INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            338

TABLE 518            INDIA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       338

TABLE 519            INDIA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            339

TABLE 520            SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            340

TABLE 521            SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            340

TABLE 522            SOUTH KOREA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            340

TABLE 523            SOUTH KOREA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         341

TABLE 524            SOUTH KOREA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)       341

TABLE 525            SOUTH KOREA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 341

TABLE 526            SOUTH KOREA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 342

TABLE 527            SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            342

TABLE 528            SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,  2022–2029 (USD MILLION)            342

TABLE 529            SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                343

TABLE 530            SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      343

TABLE 531            SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         343

TABLE 532            SOUTH KOREA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            344

TABLE 533            AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            345

TABLE 534            AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            345

TABLE 535            AUSTRALIA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         345

TABLE 536            AUSTRALIA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         346

TABLE 537            AUSTRALIA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            346

TABLE 538            AUSTRALIA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            346

TABLE 539            AUSTRALIA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            347

TABLE 540            AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            347

TABLE 541            AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            347

TABLE 542            AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 348

TABLE 543            AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            348

TABLE 544            AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)       348

TABLE 545            AUSTRALIA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            349

TABLE 546            REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,  2022–2029 (USD MILLION)            350

TABLE 547            REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,  2022–2029 (USD MILLION)            350

TABLE 548            REST OF ASIA PACIFIC: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 350

TABLE 549            REST OF ASIA PACIFIC: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)       351

TABLE 550            REST OF ASIA PACIFIC: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            351

TABLE 551            REST OF ASIA PACIFIC: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         351

TABLE 552            REST OF ASIA PACIFIC: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         352

TABLE 553            REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,  2022–2029 (USD MILLION)            352

TABLE 554            REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION)            352

TABLE 555            REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                353

TABLE 556            REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      353

TABLE 557            REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         353

TABLE 558            REST OF ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,  2022–2029 (USD MILLION)            354

TABLE 559            LATIN AMERICA: KEY MACROINDICATORS                 355

TABLE 560            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)            355

TABLE 561            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            356

TABLE 562            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            356

TABLE 563            LATIN AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            356

TABLE 564            LATIN AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            357

TABLE 565            LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)       357

TABLE 566            LATIN AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 357

TABLE 567            LATIN AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 358

TABLE 568            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            358

TABLE 569            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,  2022–2029 (USD MILLION)            358

TABLE 570            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                359

TABLE 571            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      359

TABLE 572            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         359

TABLE 573            LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            360

TABLE 574            BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            361

TABLE 575            BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            361

TABLE 576            BRAZIL: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 361

TABLE 577            BRAZIL: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 362

TABLE 578            BRAZIL: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         362

TABLE 579            BRAZIL: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            362

TABLE 580            BRAZIL: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            363

TABLE 581            BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            363

TABLE 582            BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            363

TABLE 583            BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 364

TABLE 584            BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            364

TABLE 585            BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       364

TABLE 586            BRAZIL: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            365

TABLE 587            MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            366

TABLE 588            MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            366

TABLE 589            MEXICO: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)       366

TABLE 590            MEXICO: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 367

TABLE 591            MEXICO: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         367

TABLE 592            MEXICO: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)          367

TABLE 593            MEXICO: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)          368

TABLE 594            MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            368

TABLE 595            MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)          368

TABLE 596            MEXICO: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 369

TABLE 597            MEXICO: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            369

TABLE 598            MEXICO: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       369

TABLE 599            MEXICO: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            370

TABLE 600            REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,  2022–2029 (USD MILLION)            371

TABLE 601            REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,  2022–2029 (USD MILLION)            371

TABLE 602            REST OF LATIN AMERICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            371

TABLE 603            REST OF LATIN AMERICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 372

TABLE 604            REST OF LATIN AMERICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            372

TABLE 605            REST OF LATIN AMERICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         372

TABLE 606            REST OF LATIN AMERICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         373

TABLE 607            REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,  2022–2029 (USD MILLION)            373

TABLE 608            REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       373

TABLE 609            REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                374

TABLE 610            REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      374

TABLE 611            REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         374

TABLE 612            REST OF LATIN AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,  2022–2029 (USD MILLION)            375

TABLE 613            MIDDLE EAST: KEY MACROINDICATORS                 376

TABLE 614            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY REGION,

2022–2029 (USD MILLION)          376

TABLE 615            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            376

TABLE 616            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            377

TABLE 617            MIDDLE EAST: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         377

TABLE 618            MIDDLE EAST: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         377

TABLE 619            MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)       378

TABLE 620            MIDDLE EAST: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 378

TABLE 621            MIDDLE EAST: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 378

TABLE 622            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            379

TABLE 623            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            379

TABLE 624            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                379

TABLE 625            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      380

TABLE 626            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         380

TABLE 627            MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            381

TABLE 628            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY COUNTRY,

2022–2029 (USD MILLION)          381

TABLE 629            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)          382

TABLE 630            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)          382

TABLE 631            GCC COUNTRIES: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            382

TABLE 632            GCC COUNTRIES: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)            383

TABLE 633            GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 383

TABLE 634            GCC COUNTRIES: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 383

TABLE 635            GCC COUNTRIES: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 384

TABLE 636            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)          384

TABLE 637            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,  2022–2029 (USD MILLION)            384

TABLE 638            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                385

TABLE 639            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      385

TABLE 640            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         386

TABLE 641            GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,  2022–2029 (USD MILLION)            386

TABLE 642            SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            387

TABLE 643            SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            387

TABLE 644            SAUDI ARABIA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            388

TABLE 645            SAUDI ARABIA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         388

TABLE 646            SAUDI ARABIA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)       388

TABLE 647            SAUDI ARABIA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 389

TABLE 648            SAUDI ARABIA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 389

TABLE 649            SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            390

TABLE 650            SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,  2022–2029 (USD MILLION)            390

TABLE 651            SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                390

TABLE 652            SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      391

TABLE 653            SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         391

TABLE 654            SAUDI ARABIA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            392

TABLE 655          UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            393

TABLE 656          UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            393

TABLE 657            UAE: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 393

TABLE 658            UAE: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 394

TABLE 659            UAE: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         394

TABLE 660            UAE: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            394

TABLE 661            UAE: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            395

TABLE 662          UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)          395

TABLE 663          UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            395

TABLE 664            UAE: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,

BY TYPE, 2022–2029 (USD MILLION)         396

TABLE 665            UAE: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION) 396

TABLE 666            UAE: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)            397

TABLE 667          UAE: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            397

TABLE 668            REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET,

BY PRODUCT, 2022–2029 (USD MILLION)               398

TABLE 669            REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,  2022–2029 (USD MILLION)            398

TABLE 670            REST OF GCC COUNTRIES: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            399

TABLE 671            REST OF GCC COUNTRIES: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 399

TABLE 672            REST OF GCC COUNTRIES: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)                399

TABLE 673            REST OF GCC COUNTRIES: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            400

TABLE 674            REST OF GCC COUNTRIES: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)       400

TABLE 675            REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,  2022–2029 (USD MILLION)            401

TABLE 676            REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       401

TABLE 677            REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                401

TABLE 678            REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      402

TABLE 679            REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         402

TABLE 680            REST OF GCC COUNTRIES: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION)            403

TABLE 681            REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,  2022–2029 (USD MILLION)            404

TABLE 682            REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,  2022–2029 (USD MILLION)            404

TABLE 683            REST OF MIDDLE EAST: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION) 404

TABLE 684            REST OF MIDDLE EAST: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET,  BY TYPE, 2022–2029 (USD MILLION)       405

TABLE 685            REST OF MIDDLE EAST: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE, 2022–2029 (USD MILLION)            405

TABLE 686            REST OF MIDDLE EAST: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         405

TABLE 687            REST OF MIDDLE EAST: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         406

TABLE 688            REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,  2022–2029 (USD MILLION)            406

TABLE 689            REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET,

BY APPLICATION, 2022–2029 (USD MILLION)       406

TABLE 690            REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)                407

TABLE 691            REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)      407

TABLE 692            REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)         408

TABLE 693            REST OF MIDDLE EAST: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,  2022–2029 (USD MILLION)            408

TABLE 694            AFRICA: KEY MACROINDICATORS            409

TABLE 695            AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2022–2029 (USD MILLION)            410

TABLE 696            AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2022–2029 (USD MILLION)            410

TABLE 697            AFRICA: VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 410

TABLE 698            AFRICA: RETROVIRUS-BASED GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,  2022–2029 (USD MILLION)                 411

TABLE 699            AFRICA: NON-VIRAL VECTOR-BASED GENE DELIVERY TECHNOLOGIES MARKET,

BY TYPE, 2022–2029 (USD MILLION)         411

TABLE 700            AFRICA: CHEMICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            411

TABLE 701            AFRICA: PHYSICAL GENE DELIVERY TECHNOLOGIES MARKET, BY TYPE,

2022–2029 (USD MILLION)            412

TABLE 702            AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2022–2029 (USD MILLION)            412

TABLE 703            AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2022–2029 (USD MILLION)            412

TABLE 704            AFRICA: GENE DELIVERY TECHNOLOGIES MARKET FOR RESEARCH APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION) 413

TABLE 705            AFRICA: GENE DELIVERY TECHNOLOGIES MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)            413

TABLE 706            AFRICA: GENE DELIVERY TECHNOLOGIES MARKET FOR THERAPEUTIC APPLICATIONS,  BY TYPE, 2022–2029 (USD MILLION)       414

TABLE 707            AFRICA: GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2022–2029 (USD MILLION)            414

TABLE 708            OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES                415

TABLE 709            GENE DELIVERY TECHNOLOGIES MARKET: DEGREE OF COMPETITION         418

TABLE 710            GENE DELIVERY TECHNOLOGIES MARKET: REGION FOOTPRINT     421

TABLE 711            GENE DELIVERY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 422

TABLE 712            GENE DELIVERY TECHNOLOGIES MARKET: METHOD FOOTPRINT   423

TABLE 713            GENE DELIVERY TECHNOLOGIES MARKET: APPLICATION FOOTPRINT         424

TABLE 714            GENE DELIVERY TECHNOLOGIES MARKET: END-USER FOOTPRINT 425

TABLE 715            GENE DELIVERY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES             427

TABLE 716            GENE DELIVERY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES    427

TABLE 717            GENE DELIVERY TECHNOLOGIES MARKET: PRODUCT LAUNCHES,

JANUARY 2021–SEPTEMBER 2024                430

TABLE 718            GENE DELIVERY TECHNOLOGIES MARKET: DEALS,

JANUARY 2021–SEPTEMBER 2024                431

TABLE 719            GENE DELIVERY TECHNOLOGIES MARKET: EXPANSIONS,

JANUARY 2021–SEPTEMBER 2024                432

TABLE 720            THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW          433

TABLE 721            THERMO FISHER SCIENTIFIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED    434

TABLE 722            THERMO FISHER SCIENTIFIC: PRODUCT LAUNCHES,

JANUARY 2021–SEPTEMBER 2024              441

TABLE 723            THERMO FISHER SCIENTIFIC: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024                441

TABLE 724            DANAHER CORPORATION: COMPANY OVERVIEW          443

TABLE 725            DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED    444

TABLE 726            DANAHER CORPORATION: PRODUCT LAUNCHES,

JANUARY 2021–SEPTEMBER 2024                446

TABLE 727            DANAHER CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024   447

TABLE 728            DANAHER CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024                447

TABLE 729            MERCK: COMPANY OVERVIEW  449

TABLE 730            MERCK: PRODUCTS/SERVICES/SOLUTIONS OFFERED             450

TABLE 731            MERCK: DEALS, JANUARY 2021–SEPTEMBER 2024                 453

TABLE 732            MERCK: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024              454

TABLE 733            BIO-RAD LABORATORIES: COMPANY OVERVIEW          455

TABLE 734            BIO-RAD LABORATORIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED    456

TABLE 735            AGILENT TECHNOLOGIES: COMPANY OVERVIEW          458

TABLE 736            AGILENT TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED    459

TABLE 737            AGILENT TECHNOLOGIES: DEALS, JANUARY 2021–SEPTEMBER 2024   461

TABLE 738            REVVITY: COMPANY OVERVIEW               462

TABLE 739            REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED             463

TABLE 740            REVVITY: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024              465

TABLE 741            REVVITY: DEALS, JANUARY 2021–SEPTEMBER 2024        465

TABLE 742            QIAGEN: COMPANY OVERVIEW 466

TABLE 743            QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED             467

TABLE 744            GENSCRIPT: COMPANY OVERVIEW         469

TABLE 745            GENSCRIPT: PRODUCTS/SERVICES/SOLUTIONS OFFERED             470

TABLE 746            GENSCRIPT: DEALS, JANUARY 2021–SEPTEMBER 2024        471

TABLE 747            TAKARA BIO: COMPANY OVERVIEW       472

TABLE 748            TAKARA BIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED    473

TABLE 749            TAKARA BIO: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024   479

TABLE 750            TAKARA BIO: DEALS, JANUARY 2021–SEPTEMBER 2024              479

TABLE 751            PROMEGA CORPORATION: COMPANY OVERVIEW          480

TABLE 752            PROMEGA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED    480

TABLE 753            BIO-TECHNE: COMPANY OVERVIEW      482

TABLE 754            BIO-TECHNE: PRODUCTS/SERVICES/SOLUTIONS OFFERED    483

TABLE 755            BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024   485

TABLE 756            LONZA: COMPANY OVERVIEW  486

TABLE 757            LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED             487

TABLE 758            LONZA: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024              489

TABLE 759            LONZA: DEALS, JANUARY 2021–SEPTEMBER 2024                 489

TABLE 760            OXFORD BIOMEDICA: COMPANY OVERVIEW                 490

TABLE 761            OXFORD BIOMEDICA: PRODUCTS/SERVICES/SOLUTIONS OFFERED    491

TABLE 762            OXFORD BIOMEDICA: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024                492

TABLE 763            OXFORD BIOMEDICA: DEALS, JANUARY 2021–SEPTEMBER 2024              492

TABLE 764            OXFORD BIOMEDICA: OTHER DEVELOPMENTS, JANUARY 2021–SEPTEMBER 2024                493

TABLE 765            SARTORIUS: COMPANY OVERVIEW         494

TABLE 766            SARTORIUS: PRODUCTS/SERVICES/SOLUTIONS OFFERED             495

TABLE 767            SARTORIUS: PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024   497

TABLE 768            SARTORIUS: DEALS, JANUARY 2021–SEPTEMBER 2024        497

TABLE 769            MAXCYTE: COMPANY OVERVIEW             498

TABLE 770            MAXCYTE: PRODUCTS/SERVICES/SOLUTIONS OFFERED             499

TABLE 771            MAXCYTE: DEALS, JANUARY 2021–SEPTEMBER 2024        500

LIST OF FIGURES

FIGURE 1              GENE DELIVERY TECHNOLOGIES MARKET SEGMENTATION AND REGIONAL SCOPE              49

FIGURE 2              RESEARCH DESIGN         52

FIGURE 3              BREAKDOWN OF PRIMARIES: GENE DELIVERY TECHNOLOGIES MARKET            54

FIGURE 4              GENE DELIVERY TECHNOLOGIES MARKET SIZE ESTIMATION  (SUPPLY-SIDE ANALYSIS), 2023   55

FIGURE 5              GLOBAL MARKET SIZE ESTIMATION APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023                 56

FIGURE 6              ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC: REVENUE SHARE ANALYSIS (2023)  56

FIGURE 7              MARKET SIZE VALIDATION FROM PRIMARY SOURCES             57

FIGURE 8              MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH                58

FIGURE 9              GENE DELIVERY TECHNOLOGIES MARKET: CAGR PROJECTIONS      59

FIGURE 10            DATA TRIANGULATION METHODOLOGY                 61

FIGURE 11            GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT,

2024 VS. 2029 (USD MILLION)      64

FIGURE 12            GENE DELIVERY TECHNOLOGIES MARKET, BY MODE,

2024 VS. 2029 (USD MILLION)      65

FIGURE 13            GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD,

2024 VS. 2029 (USD MILLION)      65

FIGURE 14            GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION,

2024 VS. 2029 (USD MILLION)      66

FIGURE 15            GENE DELIVERY TECHNOLOGIES MARKET, BY END USER,

2024 VS. 2029 (USD MILLION)      67

FIGURE 16            GEOGRAPHICAL SNAPSHOT OF GENE DELIVERY TECHNOLOGIES MARKET      68

FIGURE 17            INCREASED INVESTMENTS IN GENE THERAPY RESEARCH TO DRIVE MARKET  69

FIGURE 18            RESEARCH APPLICATIONS HELD LARGEST MARKET SHARE IN NORTH AMERICA (2023)         70

FIGURE 19            VIRAL VECTORS SEGMENT TO DOMINATE MARKET TILL 2029           70

FIGURE 20            CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2029          71

FIGURE 21            GENE DELIVERY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES                 72

FIGURE 22            US: PREVALENCE OF CANCER, 2017–2023                 73

FIGURE 23            GENE DELIVERY TECHNOLOGIES MARKET: ECOSYSTEM       78

FIGURE 24            AVERAGE SELLING PRICE TREND OF GENE DELIVERY INSTRUMENTS,

2023 (USD THOUSAND) 84

FIGURE 25            GENE DELIVERY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS               85

FIGURE 26            GENE DELIVERY TECHNOLOGIES MARKET: SUPPLY CHAIN ANALYSIS             86

FIGURE 27            GENE DELIVERY TECHNOLOGIES MARKET: OVERVIEW OF PATENTING ACTIVITY    88

FIGURE 28            GENE DELIVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS           96

FIGURE 29            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS              98

FIGURE 30            KEY BUYING CRITERIA FOR TOP THREE END USERS   99

FIGURE 31            REVENUE SHIFT IN GENE DELIVERY TECHNOLOGIES MARKET            101

FIGURE 32            GENE DELIVERY TECHNOLOGIES MARKET: IMPACT OF AI   103

FIGURE 33            NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET SNAPSHOT    264

FIGURE 34            ASIA PACIFIC: GENE DELIVERY TECHNOLOGIES MARKET SNAPSHOT       318

FIGURE 35            REVENUE ANALYSIS OF KEY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET, 2021–2023 417

FIGURE 36            MARKET SHARE ANALYSIS OF KEY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET, 2023               418

FIGURE 37            GENE DELIVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023     420

FIGURE 38            GENE DELIVERY TECHNOLOGIES MARKET: COMPANY FOOTPRINT 421

FIGURE 39            GENE DELIVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023                 426

FIGURE 40            EV/EBITDA OF KEY VENDORS   428

FIGURE 41            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF

KEY VENDORS  428

FIGURE 42            GENE DELIVERY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     429

FIGURE 43            THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT          434

FIGURE 44            DANAHER CORPORATION: COMPANY SNAPSHOT          444

FIGURE 45            MERCK: COMPANY SNAPSHOT  450

FIGURE 46            BIO-RAD LABORATORIES: COMPANY SNAPSHOT          456

FIGURE 47            AGILENT TECHNOLOGIES: COMPANY SNAPSHOT          459

FIGURE 48            REVVITY: COMPANY SNAPSHOT               463

FIGURE 49            QIAGEN: COMPANY SNAPSHOT                 467

FIGURE 50            GENSCRIPT: COMPANY SNAPSHOT         470

FIGURE 51            TAKARA BIO: COMPANY SNAPSHOT       473

FIGURE 52            BIO-TECHNE: COMPANY SNAPSHOT      483

FIGURE 53            LONZA: COMPANY SNAPSHOT  487

FIGURE 54            OXFORD BIOMEDICA: COMPANY SNAPSHOT                 491

FIGURE 55            SARTORIUS: COMPANY SNAPSHOT         495

FIGURE 56            MAXCYTE: COMPANY SNAPSHOT             499

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧